$0.98-0.00 (-0.28%)
INVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients.
INVO Fertility, Inc. in the Healthcare sector is trading at $0.98 with a market capitalization of $2M. Wall Street consensus targets $20.00 (1 analysts), implying a +1936.2% move over the next 12 months. The stock is currently near its 52-week low of $0.90, remaining 71.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 14 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.02Mβ | $1.58Mβ | $1.76Mβ | $1.86Mβ | $1.64M |
| Gross Profit | $727,826β | $536,860β | $629,345β | $770,051β | $592,256 |
| Operating Income | -$1.59Mβ | -$1.41Mβ | -$1.64Mβ | -$1.59Mβ | -$1.20M |
| Net Income | -$5.54Mβ | $2.01Mβ | -$2.64Mβ | -$5.28Mβ | -$17.40M |
INVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients. It operates through Fertility Clinic Services and INVOcell Device segments. The company offers ...
INVO Fertility Inc (IVF) reports strong quarterly growth driven by the Family Beginnings acquisition and improved operational efficiency.

INVO Fertility (NASDAQ:IVF) reported a 17% increase in second-quarter 2026 revenue to $2. 18 million as the first full-quarter contribution from Family Beginnings and growth initiatives across its existing clinics expanded the fertility services platform.
AI infrastructure plan, SpaceX exposure, and Nasdaq compliance update boosted investor sentiment.
Nu Holdings Ltd. 46,657,078 18.56
INVO Fertility stock has more than quadrupled in recent days without any concrete catalyst. Hereβs why investors are cautioned against investing in IVF shares at current levels.